Syndax Pharmaceuticals (SNDX) Metrics: History & Chart

Syndax Pharmaceuticals, Inc.(SNDX)

Biotechnology · New York City, NY

$17.37-0.46 (-2.58%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.

New York City, NY

298 employees

www.syndax.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Michael A. Metzger

View full financials

Third-Party DCF Estimate (FMP)	$12.73
Price Gap vs Third-Party Estimate	-27.50%

7D Total Return	-0.17%
30D Total Return	-13.28%
YTD Total Return	-15.14%
1Y Total Return	+14.29%
3Y Total Return	+38.85%
5Y Total Return	-0.05%
10Y Total Return	+10.90%
15Y Total Return	N/A
20Y Total Return	N/A

2026	-15.14%
2025	+58.93%
2024	-38.82%
2023	-15.09%
2022	+16.26%
2021	-1.57%
2020

CAGR TTM	+14.22%
CAGR 3Y	+11.56%
CAGR 5Y	-0.01%
CAGR 10Y	+1.04%
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	139.56
PE Ratio Avg TTM	83.66
PE Ratio Avg 3Y	83.66
Current VS TTM Avg	+66.83%
Current VS 3Y Avg	+66.83%
Current VS 5Y Avg	+66.83%

All Metrics

SNDX Valuation Metrics

SNDX Stock Price Metrics

SNDX Dividend Metrics

SNDX Growth Rate Metrics

SNDX Discounted Cash Flow Metrics

SNDX Returns By Period

SNDX Yearly Returns

SNDX Average Annual Returns By Period (CAGR)

SNDX Revenue Metrics

SNDX PE Ratio Metrics

SNDX PS Ratio Metrics

SNDX PB Ratio Metrics

SNDX Price to Free Cash Flow Ratio Metrics

SNDX Debt to Equity Ratio Metrics

SNDX PEG Ratio Metrics

SNDX FCF Yield

SNDX Earnings Yield

SNDX EBITDA Yield

SNDX OCF Yield

SNDX EV/EBIT Ratio Metrics

SNDX EV/EBITDA Ratio Metrics

SNDX EV/Assets Ratio Metrics

SNDX EV/Sales Ratio Metrics

SNDX Current Ratio Metrics

SNDX Quick Ratio Metrics

SNDX ROIC Metrics

SNDX Return on Assets Metrics

SNDX Return on Equity Metrics

SNDX Net Profit Margin Metrics

SNDX Gross Profit Margin Metrics

SNDX Tax Rate Metrics

PS Ratio	6.30
PS Ratio Avg TTM	11.47
PS Ratio Avg 3Y	27.48
Current VS TTM Avg	-45.08%
Current VS 3Y Avg	-77.08%
Current VS 5Y Avg	-75.23%

PB Ratio	105.09
PB Ratio Avg TTM	26.25
PB Ratio Avg 3Y	7.23
Current VS TTM Avg	+300.39%
Current VS 3Y Avg	+1353.90%
Current VS 5Y Avg	+2786.65%

PFCF Ratio	146.29
PFCF Ratio Avg TTM	74.54
PFCF Ratio Avg 3Y	74.54
Current VS TTM Avg	+96.27%
Current VS 3Y Avg	+96.27%
Current VS 5Y Avg	+96.27%

Debt/Equity Ratio	39.03
Debt/Equity Ratio Avg TTM	11.14
Debt/Equity Ratio Avg 3Y	0.87
Current VS TTM Avg	+250.42%
Current VS 3Y Avg	+4375.55%
Current VS 5Y Avg	+148505.68%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	0.68%
FCF Yield Avg TTM	1.93%
FCF Yield Avg 3Y	1.93%
Current VS TTM Avg	-64.77%
Current VS 3Y Avg	-64.77%
Current VS 5Y Avg	-64.77%

Earnings Yield	0.72%
Earnings Yield Avg TTM	1.64%
Earnings Yield Avg 3Y	1.64%
Current VS TTM Avg	-56.18%
Current VS 3Y Avg	-56.18%
Current VS 5Y Avg	-56.18%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	1096.16
Ev/Ebit Ratio Avg TTM	449.30
Ev/Ebit Ratio Avg 3Y	449.30
Current VS TTM Avg	+143.97%
Current VS 3Y Avg	+143.97%
Current VS 5Y Avg	+143.97%

Ev/Ebitda Ratio	967.45
Ev/Ebitda Ratio Avg TTM	399.33
Ev/Ebitda Ratio Avg 3Y	399.33
Current VS TTM Avg	+142.27%
Current VS 3Y Avg	+142.27%
Current VS 5Y Avg	+142.27%

Ev/Assets Ratio	2.61
Ev/Assets Ratio Avg TTM	3.56
Ev/Assets Ratio Avg 3Y	2.83
Current VS TTM Avg	-26.68%
Current VS 3Y Avg	-7.87%
Current VS 5Y Avg	-9.76%

Ev/Sales Ratio	7.30
Ev/Sales Ratio Avg TTM	12.64
Ev/Sales Ratio Avg 3Y	26.92
Current VS TTM Avg	-42.23%
Current VS 3Y Avg	-72.88%
Current VS 5Y Avg	-70.17%

Current Ratio	6.77
Current Ratio Avg TTM	5.20
Current Ratio Avg 3Y	7.49
Current VS TTM Avg	+30.33%
Current VS 3Y Avg	-9.53%
Current VS 5Y Avg	-34.52%

Quick Ratio	6.44
Quick Ratio Avg TTM	4.92
Quick Ratio Avg 3Y	7.38
Current VS TTM Avg	+30.91%
Current VS 3Y Avg	-12.69%
Current VS 5Y Avg	-37.32%

ROIC	(32.15%)
ROIC Avg 3Y	(57.79%)
ROIC Avg 5Y	(42.63%)
Current VS 3Y Avg	+44.37%
Current VS 5Y Avg	+24.58%
Current VS 10Y Avg	+37.00%

ROA	(31.37%)
ROA Avg TTM	(10.39%)
ROA Avg 3Y	(12.16%)
Current VS TTM Avg	-201.99%
Current VS 3Y Avg	-158.01%
Current VS 5Y Avg	-193.90%

ROE	(1462.12%)
ROE Avg TTM	(332.56%)
ROE Avg 3Y	(128.49%)
Current VS TTM Avg	-339.66%
Current VS 3Y Avg	-1037.94%
Current VS 5Y Avg	-2579.62%

Net Profit Margin	(87.60%)
Net Profit Margin Avg TTM	(110.91%)
Net Profit Margin Avg 3Y	(150.08%)
Current VS TTM Avg	+21.02%
Current VS 3Y Avg	+41.63%
Current VS 5Y Avg	-39.35%

Gross Profit Margin	97.47%
Gross Pft Margin Avg TTM	97.18%
Gross Pft Margin Avg 3Y	67.81%
Current VS TTM Avg	+0.30%
Current VS 3Y Avg	+43.75%
Current VS 5Y Avg	+73.26%

Tax Rate	0.00%
Tax Rate Avg 3Y	N/A
Tax Rate Avg 5Y	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A
Current VS 10Y Avg	N/A